# Minimally Invasive Surgery and Recurrence Risk in Borderline Ovarian Tumours: A 10-Year Cohort Analysis

**Authors:** Mohamed Abdelwanis Mohamed Abdelaziz, Ambreen Yaseen, Tasrina Akter, Siddesh Prabhulingam, Nesma Hesham, Hossam Ali, David Nunns

PMC · DOI: 10.3390/medicina62020326 · 2026-02-05

## TL;DR

This study found that minimally invasive surgery for borderline ovarian tumors may increase recurrence risk, especially in fertility-sparing procedures.

## Contribution

The study provides new evidence on the oncological safety of minimally invasive surgery for borderline ovarian tumors.

## Key findings

- Minimally invasive surgery was linked to higher recurrence rates compared to open surgery.
- The risk difference was 15.5% with a hazard ratio of 5.29 for MIS versus open surgery.
- The association was more pronounced in fertility-sparing procedures.

## Abstract

Background and Objectives: Borderline ovarian tumours (BOTs) predominantly affect women of reproductive age. Following concerns about minimally invasive surgery (MIS) in cervical cancer, the oncological safety of the surgical approach in BOTs requires evaluation, particularly in fertility-sparing procedures where clinical implications are greatest. This study aimed to assess whether MIS is associated with increased recurrence risk in BOTs, with stratified analysis by fertility-sparing status based on a pre-specified hypothesis of differential effects. Materials and Methods: Single-centre cohort study of 91 BOT patients treated at Nottingham City Hospital Cancer Centre between 2014–2023. The primary outcome was progression-free survival comparing MIS versus open surgical approaches. Results: Minimally invasive surgery was associated with higher observed recurrence compared to open surgery (5/25 [20.0%, 95% CI: 6.8–40.7%] vs. 3/66 [4.5%, 95% CI: 0.9–12.7%], absolute risk difference 15.5% [95% CI: 2.1–28.9%]; unadjusted HR 5.29, 95% CI: 1.26–22.17; p = 0.022). Conclusions: This study identifies an association between minimally invasive surgery and higher recurrence in borderline ovarian tumours, particularly in fertility-sparing procedures. While based on small numbers necessitating cautious interpretation, the consistency across analytical approaches, substantial magnitude of observed differences, and biological plausibility warrant validation in larger cohorts to inform surgical counselling.

## Linked entities

- **Diseases:** cervical cancer (MONDO:0002974)

## Full-text entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** mucinous (MESH:D002288), stage III disease (MESH:D007676), FSS (MESH:D007246), Metastases (MESH:D009362), adhesions (MESH:D000267), IVF (MESH:C566179), MIS (MESH:D009361), cyst (MESH:D003560), BOT (MESH:C041229), BOT (MESH:D010051), mucinous tumours (MESH:D018297), peritoneal carcinomatosis (MESH:D010534), rupture (MESH:D012421), Tumour (MESH:D009369), IC (MESH:C537984), injury to (MESH:D014947), Cervical Cancer (MESH:D002583), IC disease (MESH:C562805)
- **Chemicals:** CO2 (MESH:D002245)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942151/full.md

---
Source: https://tomesphere.com/paper/PMC12942151